Patents by Inventor Mads Nikolaj Holten-Andersen

Mads Nikolaj Holten-Andersen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • TISSUE INHIBITOR OF MATRIX METALLOPROTEINASES TYPE-1 (TIMP-1) AS A CANCER MARKER AND POSTOPERATIVE MARKER FOR MINIMAL RESIDUAL DISEASE OR RECURRENT DISEASE IN PATIENTS WITH A PRIOR HISTORY OF CANCER
    Publication number: 20110294148
    Abstract: The present invention describes a method for determining whether an individual is suffering from cancer by determining a parameter representing the TIMP-1 concentration in body fluid samples from the individual. The present invention furthermore describes a method for determining whether an individual is suffering from minimal residual disease or recurrent cancer after being treated for the primary cancer by determining a parameter representing the post-operative TIMP-1 concentration in body fluid samples from the individual. In addition, the invention describes the additive effect of combined post-operative measurements of plasma TIMP-1 and serum CEA.
    Type: Application
    Filed: August 4, 2011
    Publication date: December 1, 2011
    Applicants: HVIDOVRE HOSPITAL, RIGSHOSPITALET
    Inventors: Mads Nikolaj Holten-Andersen, Ib Jarle Christensen, Nils Brünner, Hans Jørgen Nielsen
  • TISSUE INHIBITOR OF MATRIX METALLOPROTEINASES TYPE-1 (TIMP-1) AS A CANCER MARKER AND POSTOPERATIVE MARKER FOR MINIMAL RESIDUAL DISEASE OR RECURRENT DISEASE IN PATIENTS WITH A PRIOR HISTORY OF CANCER
    Publication number: 20080261246
    Abstract: The present invention describes a method for determining whether an individual is suffering from cancer by determining a parameter representing the TIMP-1 concentration in body fluid samples from the individual. The present invention furthermore describes a method for determining whether an individual is suffering from minimal residual disease or recurrent cancer after being treated for the primary cancer by determining a parameter representing the post-operative TIMP-1 concentration in body fluid samples from the individual. In addition, the invention describes the additive effect of combined post-operative measurements of plasma TIMP-1 and serum CEA.
    Type: Application
    Filed: April 11, 2008
    Publication date: October 23, 2008
    Applicants: RIGSHOSPITALET, HVIDOVRE HOSPITAL
    Inventors: Mads Nikolaj Holten-Andersen, Ib Jarle Christensen, Nils Brunner, Hans Jorgen Nielsen
  • Tissue inhibitor of matrix metalloproteinases type-1 (TIMP-1) as a cancer marker and postoperative marker for minimal residual disease or recurrent disease in patients with a prior history of cancer
    Patent number: 7374886
    Abstract: The present invention describes a method for determining whether an individual is suffering from cancer by determining a parameter representing the TIMP-1 concentration in body fluid samples from the individual. The present invention furthermore describes a method for determining whether an individual is suffering from minimal residual disease or recurrent cancer after being treated for the primary cancer by determining a parameter representing the post-operative TIMP-1 concentration in body fluid samples from the individual. In addition, the invention describes the additive effect of combined post-operative measurements of plasma TIMP-1 and serum CEA.
    Type: Grant
    Filed: April 8, 2002
    Date of Patent: May 20, 2008
    Assignees: Rigshospitalet, Hvidovre Hospital
    Inventors: Mads Nikolaj Holten-Andersen, Ib Jarle Christensen, Nils Brünner, Hans Jørgen Nielsen
  • Tissue inhibitor of matrix metalloproteinases type-1 (TIMP-1) as a cancer marker and postoperative marker for minimal residual disease or recurrent disease in patients with a prior history of cancer
    Publication number: 20030082652
    Abstract: The present invention describes a method for determining whether an individual is suffering from cancer by determining a parameter representing the TIMP-1 concentration in body fluid samples from the individual.
    Type: Application
    Filed: April 8, 2002
    Publication date: May 1, 2003
    Inventors: Mads Nikolaj Holten-Andersen, Ib Jarle Christensen, Nils Brunner, Hans Jorgen Nielsen